Revenues in line with prior year, growing portfolio of customers across a range of neurological indications and a changing sales mix

IXICO today provides the following pre-close trading update ahead of its preliminary results for the year ended 30 September 2016.

The Company is pleased to report revenues for the year of £3.1 million (2015: £3.1 million) and other income of £0.7 million, giving total income of £3.8 million for the year (2015: £4.2 million). Revenues were in line with the prior year and reflected the start-up of seven new clinical trials including five Alzheimer’s disease studies, one in progressive supranuclear palsy (PSP) and a first contract in Parkinson’s Disease with Oxford Biomedica. The project start-up activities included the US$7 million long term contract with a leading pharmaceutical company announced in August 2015.

By |2017-10-10T15:20:16+00:0021 October 2016|Financial|